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BACKGROUND	  
	  
High-­‐grade	   atrioventricular	   block	   (HABV)	   is	   associated	  with	   poorer	  
outcomes	   in	   the	   seKng	   of	   acute	   coronary	   syndromes.	   Limited	  
informa3on	  is	  available	  on	  the	  incidence	  and	  death	  associated	  with	  






To	   evaluate	   the	   incidence	   of	   HABV	   and	   its	   impact	   on	  
outcome	  of	  STEMI	  pts,	  in	  primary	  percutaneous	  coronary	  
interven3on	  era.	  
1149	  STEMI	  pts	  admiRed,	  
consecu3vely,	  in	  our	  coronary	  
unit,	  from	  July	  of	  2009	  to	  June	  
2014	  
Group	  1	  	  
	  Pts	  without	  HABV	  	  
(n=1057,	  92%)	  
Group	  2	  	  
Pts	  with	  HABV	  	  
(n=92,	  8%)	  
HABV	  was	  defined	  as	  the	  
presence	  of	  either	  Mob9z	  
II	  2nd	  degree	  AV	  block	  or	  
3rd	  degree	  AV	  block.	  





•  Primary	  endpoint	  was	  the	  occurrence	  of	  death	  at	  6	  months.	  




Besides	   low	   incidence	  of	  HABV,	  this	  complica3on	  con3nues	  to	  have	  a	  high	  risk	  of	   in-­‐hospital	  and	  6-­‐month	  mortality	  











































































































































43,5%	  had	  HABV	  on	  
admission	  
71,4	   71,4	  
100	  
7,1	  










Temp.	  PM	   KK	  >1	   LSVD	   RSVD	  
AMI	  
IMI	  
Compared	  with	  IMI,	  AMI	  pts	  had	  higher	  risk	  of	  in-­‐hospital	  [OR	  9.04,	  95%	  CI	  
(2.87-­‐28.50);p<0.001]	  and	  6-­‐month	  mortality	  [OR	  10.88;	  95%	  CI	  (3.33–
35.53);p<0.001].	  	  




HABV	  pa9ents	  had	  higher	  
risk	  of	  overall	  6-­‐month	  
mortality	  compared	  to	  
those	  without	  HABV	  [OR	  
2.18,	  95%	  CI	  
(1.25-­‐3.79);p=0.006].	  
Table	  I	  –	  Baseline	  pa3ents’	  characteris3cs.	  
Table	  II	  –	  Clinical	  features,	  treatment	  and	  adverse	  events	  
Fig	  1	  –	  Clinical	  differences	  between	  AMI	  and	  IMI	  pts.	  
Fig	  2	  –	  Survival	  analyses	  by	  Kaplan-­‐Meyer	  survival	  curves.	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